small molecule

LINZESS

LINACLOTIDE

Loss of exclusivityFebruary 2034latest FDA-listed patent expiry

CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	LINZESS
Active ingredient	LINACLOTIDE
Strength	72MCG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	January 2017
Marketing status	RX

Listed patents

Patent	Expires	Type
9708371*PED	February 2034	—
9708371	August 2033	product
10702576*PED	February 2032	—
10675325*PED	February 2032	—
8933030*PED	August 2031	—
10702576	August 2031	use U-3644
10675325	August 2031	product
8933030	February 2031	product
7304036*PED	February 2027	—
7304036	August 2026	substance, product

Regulatory exclusivity

Code	Expires
NPP	May 2029
I-921	June 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from AbbVie Inc.